

A
Overall relapse by ROR1 status
% w/o Relapse
Metastasis-free survival (months)
ROR1L 0-33rd
ROR1M 34th-67th
ROR1H 68th-100th
Relapse status
n Yes No
ROR1L 194 68 126
ROR1M 194 81 113
ROR1H 194 115 76
p<0.0001
B
-1.5
0.2
1.5
ROR1
SNAI2
ZEB1
VIM
CDH2
CDH1
TJP3
TJP1
CLDN3
C
MDA-MB-231 HS-578T BT549
CTRL-siRNA
ROR1-siRNA
8h after transfection
24h after transfection
ROR1
SNAI1
SNAI2
ZEB1
ROR1
KRT19
CDH1
TJP1
VIM
CDH2
D
CTRL-shRNA
ROR1-shRNA
Snail1
Snail2
ZEB1
CK19
ZO-1
Vimentin
N-Cadherin
ROR1
β-actin
MDA-MB-231
HS-578T
BT549
E
MCF7-CTRL
MCF7-ROR1
Snail1
Snail2
E-Cadherin
CK19
ROR1
β-actin

FIG. 1



A
CTRL-shRNA
ROR1-shRNA
MDA-MB-231 (40 x)
HS-578T (40 x)
BT549 (40 x)
B
DAPI/CK-19
DAPI/E-Cad
DAPI/Vimentin
231-CTRL-shRNA (63 x)
231-ROR1-shRNA (63x)
C
MCF7-CTRL (40 x)
MCF7-ROR1 (40 x)
D
DAPI/CK-19
DAPI/E-Cad
DAPI/Vimentin
MCF7-CTRL (63 x)
MCF7-ROR1 (63x)
E
CTRL-shRNA ROR1-shRNA
Relative Migration(%)
MDA-MB-231
HS-578T
BT549
CTRL-shRNA ROR1-shRNA
Relative Invasion(%)
MDA-MB-231
HS-578T
BT549
F
CTRL-shRNA
ROR1-shRNA
Migration
Invasion

FIG. 2



A
Stage I
Stage II
Mammary Tumor
Tumor Removal
300mm3
Lung Mets
Bone Mets
Liver Mets
(4-5wks)
B
Stage I Primary Tumor Growth
Primary Tumor Removal
Tumor Volume (mm3)
CTRL-shRNA (n=7)
Ror1-shRNA (n=7)
Time (days)
C
Primary Tumor Weight
Tumor weight (g)
N.S.
CTRL-shRNA (n=7)
Ror1-shRNA (n=7)
D
Primary Tumor Photons
Primary Tumor Photons(Log)
N.S.
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
E
Day 0 of Stage II
Lung photons/primary tumor photons x1000
**
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
F
Day 0 of Stage II
Liver photons/primary tumor photons x1000
**
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
G
Lung Bioluminescence During Stage II
Normalized Photon Flux x100
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
Days Post-OP
H
Day 21 of Stage II
p<0.01
Photon Flux of extirpated Lung (Log)
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
CTRL-shRNA
ROR1-shRNA
p/sec/cm^2/sr
I
Day 21 of Stage II
Lung Weight Index (g/g X1000)
***
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
J
CTRL- shRNA
ROR1-shRNA
K
Day 21 of Stage II
p<0.05
Photon Flux of extirpated Liver (Log)
CTRL-shRNA (n=7)
ROR1-shRNA (n=7)
CTRL-shRNA
ROR1-shRNA
p/sec/cm^2/sr
L
CTRL-shRNA
ROR1-shRNA

FIG. 3



A
CTRL-shRNA(n=6)
ROR1-shRNA(n=6)
Free Survival
p<0.001
Time (day)
B
Tail vein injection
Lung colonization
CTRL-shRNA (n=5)
ROR1-shRNA (n=5)
Normalized Photon Flux
Days after xenografting
Days
CTRL-shRNA
ROR1-shRNA
p/sec/cm^2/sr
C
Day 3
CTRL-shRNA
ROR1-shRNA
40X
D
Day 21
CTRL-shRNA
ROR1-shRNA
10X
E
Day28
CTRL-shRNA
ROR1-shRNA
40X
F
p/sec/cm^2/sr
Lung ex vivo GFP Photons (p/sec/cm^2/sr x 10^7)
CTRL-shRNA (n=5)
ROR1-shRNA (n=5)
***
G
Lung Weight Index (g/g x1000)
CTRL-shRNA (n=5)
ROR1-shRNA (n=5)
***
H
CTRL-shRNA (n=5)
ROR1-shRNA (n=5)
Free survival
p<0.002
Time (day)
I
Intracardiac injection
Bone metastasis
Day 0 7 14 21
CTRL-shRNA
ROR1-shRNA
Analysis Area
p/sec/cm^2/sr
J
Day 21
Normalized Photon Flux x 1000
CTRL-shRNA (n=6)
ROR1-shRNA (n=6)
**
K
Day 21
Bone ex vivo luciferase photons (p/sec/cm^2/sr)
CTRL-shRNA (n=6)
ROR1-shRNA (n=6)
*
L
CTRL-shRNA
ROR1-shRNA
CTRL-shRNA
ROR1-shRNA

FIG. 4



A
37°C 4°C
Relative Cell Number
Fluorescence intensity
D10-Alex647
B
0min
60min
C
ROR1 Surface Expression (MFI)
***
(-) (n=3)
IgG (n=3)
D10 (n=3)
D
IgG
D10
0h 1h 4h 24h
Vimentin
β-actin
1 1.31 0.62 0.85
1 0.34 0.35 0.40
E
IgG + -
ROR1 - +
α-Vimentin
α-ROR1
F
Relative Percentage(%)
**
IgG D10
Migration(n=3)
Invasion (n=3)
G
IgG
D10
Migration(X20)
Invasion(X20)
H
Day 3
Normalization Photon Flux
***
IgG (n=5)
D10 (n=5)
HE (X40)
I
IgG (n=5)
D10 (n=5)
Normalization Photo Flux
Day0 Day1 Day2 Day14 Day21 Day28 Day35
J
Day 0 Day 1 Day 8 Day 14 Day 21 Day 28 Day 35
IgG
D10
K
Day 35
Lung Weight Index (g/Kg)
**
IgG (n=5)
D10 (n=5)
L
Day 35
IgG
D10
HE (X10)

FIG. 5



40 aa
130 aa
70 aa
70 aa
5
6
13
14
P D I L N D T L S I E S Y
P D T I D G S I A N E S Y
L A I L N D S I A N K T S
P D T I D G T L S I E S Y
mIg-like
hIg-like

FIG. 6

1. HuROR1
2. HuROR1 With E->K @138
3. HuROR1 With S->T @142
4. HuROR1 With Y->S @160
5. HuROR1 With E->K @138 & S->T @142
6. HuROR1 With E->K @138 & Y->S @160
7. HuROR1 With & S->T @142 & Y->S @160

FIG. 7



#14
mROR1
P D T I D G T L S I E S Y
P D T I D G S I A N K T S
88
105
109
111
1 2 3 4 5
1. HuROR1 with T->S @ 88
2. HuROR1 with L->I @ 105
3. HuROR1 with S-> @ 109
4. HuROR1 with I->N @ 111
5. HuROR1

FIG. 8



A
% Max
D10-Alexa647
B
0min
60min
C
ROR1 Surface Expression (MFI)
Time for mAb Tx (h)
***
D
hIgG
ROR1
α-ROR1 IP
α-Vimentin
α-ROR1
E
mIgG
D10
0h 1h 4h 24h
1 1.31 0.62 0.85
1 0.34 0.35 0.42
Vimentin
β-actin
F
Migration Cells (Transwell)
**
mIgG
D10

FIG. 9



G
Day 2
Normalization Photo Flux
m@hROR1-D10
Control IgG
HE (X40)
H
Control IgG
m@hROR1-D10
Normalization Photo Flux
Day 0
Day 2
Day 4
Day 7
Day 14
Day 21
Day 28
I
Control IgG
@ROR1-D10
J
Lung/body Coefficient
(0/00)
Control IgG
m@hROR1-D10
K
Control IgG
m@hROR1-D10
HE (X10)

FIG. 9 (cont'd)



#6
mROR1
P D T I D G S I A N E S Y
P D T I D G S I A N K T S
138 142 160
1 2 3 4 5 6 7
D10
99961
99451
99221
1. HuROR1
2. HuROR1 With E->K @138
3. HuROR1 With S->T @142
4. HuROR1 With Y->S @160
5. HuROR1 With E->K @138 & S->T @142
6. HuROR1 With E->K @138 & Y->S @160
7. HuROR1 With & S->T @142 & Y->S @160

FIG. 10




FIG. 11



A
Total CD5+B220lo Leukemia Cells in Spleen
2.0×10^8
1.5×10^8
1.0×10^8
5.0×10^7
0
mIgG
10
3
10
3
D10(mg/kg)
99661(mg/kg)
B
Percentage Free
Concentration (M)
C
Total CD5+B220lo Leukemia Cells in Spleen
2.0×10^8
1.5×10^8
1.0×10^8
5.0×10^7
0
mIgG
10
3
10
3
D10(mg/kg)
99661(mg/kg)

FIG. 12



A
% of residual CLL
150
100
50
0
CB+ mice
29%
1.5%
∅
hIgG c961 mD10
B
Human B cells
#Live human CD19+ cells
200
150
100
50
0
PBS
hIgG
Antibody treatment
C
Human T cells
#Live human CD3+ cells
15000
10000
5000
0
PBS
hIgG
Antibody treatment

FIG. 13



A
Control IgG (50µg/mL)
99961 (50µg/mL)
B
Primary colonies
CB
AML ROR1+ (n=6)
AML ROR1- (n=4)
p=0.016
Survival (% of control)
dose (ug/ml)
C
Secondary colonies
CB
AML ROR1+ (n=6)
AML ROR1- (n=4)
p=0.024
Self-renewal (% of control)
dose (ug/ml)

FIG. 14



ROR1 Expression
Normalized Expression
1400
1200
1000
800
600
400
200
0
PL HSPC
FL HSPC
EB HSPC

FIG. 15



Negative control
ROR1+ Lymphoma
Heart
Brain
Ovary
Prostate
Breast
Cerebellum
Colon
Esophagus
Adipose
Pancreas
duct
edge of islet

FIG. 16



A
Individual
1000
100
10
1
Conc (μg/mL)
0
20
40
60
80
100
Time (Day)
A
B
C
D
E
B
Average
1000
100
10
1
Conc (μg/mL)
0
20
40
60
80
100
Time (Day)

FIG. 17



ROR1 protein immunization
mAbs: 4A5 D10 K19
Peptides: A19 R22 K19
Ig-like domain
CRD domain
Kringle domain
TM domain
Tyrosine kinase domain
4A5
D10
K19
ROR1
A19
R22
K19
P D T I D G S I A N K T S V S T
Ig-like
CRD
Kringle
hROR1-ex
mROR1-ex

FIG. 18




FIG. 19



D10 and 99961 binding site
hROR1-ex P D T I D G S I A N E S Y
VATNGKEVVSSTGVLFVKFGPC (22 aa)

FIG. 20




FIG. 21

Group	Mouse	Number	Immunization	Injection	Amount
1	BALB/c	N=5	(-)	(-)	(-)
2	BALB/c	N=5	KLH	s.c	100 μg/mouse
3	BALB/c	N=5	R22-KLH	s.c	100 μg/mouse




FIG. 22



Pre immunization
After immunization
5
6
13
14
5
6
13
14
5 P D I L N D T L S I E S Y
6 P D T I D G S I A N E S Y
13 L A I L N D S I A N K T S
14 P D T I D G T L S I E S Y
Mouse ROR1
Human ROR1

FIG. 23

Group	Mouse	Number	Immunization	Injection	Amount
1	C57BL/6	N=8	(-)	(-)	(-)
2	C57BL/6	N=8	KLH	s.c	100 μg/mouse
3	C57BL/6	N=8	R22-KLH	s.c	100 μg/mouse




FIG. 24



100
80
60
40
20
0
% of Max
10^0
10^1
10^2
10^3
10^4
4A5-Alex647
Isotype
Anti-ROR1 serum #1 @ 4°C
Anti-ROR1 serum #2 @ 4°C
Anti-ROR1 serum #1 @ 37°C
Anti-ROR1 serum #2 @ 37°C

FIG. 25



A
Migration
No treatment
Pre-bleed serum
Anti-KLH serum
Anti-ROR1 serum #1
Anti-ROR1 serum #2
B
Relative Migration (%)
120
100
80
60
40
20
0
**
**
No treatment
Pre-bleed serum
No treatment
Anti-KLH serum
No treatment
Anti-ROR1 serum #1
No treatment
Anti-ROR1 serum #2

FIG. 26

Group	Mouse Number	Immunization	Injection	Amount
1	C57BL/6 N=6	(-)	(-)	(-)
2	C57BL/6 N=6	KLH	s.c	100 μg/mouse
3	C57BL/6 N=6	R22-KLH	s.c	100 μg/mouse




FIG. 27



R22 immunized B6 mice (4 weeks)
R22 immunized ROR1-Tg mice (4 weeks)
A19 immunized B6 mice (4 weeks)
A19 immunized ROR1-Tg mice (4 weeks)
K19 immunized B6 mice (4 weeks)
K19 immunized ROR1-Tg mice (4 weeks)
Absorbance (450 nm)
Dilution Factor
#1 antisera
#2 antisera
#3 antisera
#4 antisera
#5 antisera
#6 pre-bleed

FIG. 28




FIG. 29



Percent Viability
100
80
60
40
20
0
EW36
Jeko-1
CLL-1
CLL-2
Cells only
Complement only
1/2700 sera+complement
1/900 sera+complement
1/300 sera+complement
1/100 sera+complement
D10 mAb only
D10 mAb+complement

FIG. 30

Group	Mouse	Number	Immunization	Injection	Amount
1	C57BL/6	N=6	(-)	(-)	(-)
2	C57BL/6	N=6	KLH	s.c	100 μg/mouse
3	C57BL/6	N=6	R22-KLH	s.c	100 μg/mouse




FIG. 31



A
KLH
R22
B
CD5dull B220+ Leukemia %
30
20
10
0
KLH
R22
*
CD5dull B220+ Leukemia
(Total Cells/Spleen)
2.0×10^08
6.3×10^07
2.0×10^07
6.3×10^06
2.0×10^06
KLH
R22
*

FIG. 32

Group	Mouse	Number	Immunization	Injection	Amount
1	C57BL/6	N=4	(-)	(-)	(-)
2	C57BL/6	N=4	KLH	s.c	100 μg/mouse
3	C57BL/6	N=4	R22-KLH	s.c	100 μg/mouse




FIG. 33



Inhibition of Engraftment of ROR1+ Leukemia by
R22 Vaccination T C57BL/6 mice
A
KLH
R22
B
CD5dull B220+ Leukemia
(Total Cells/Spleen)
1.0×10^10
1.0×10^09
1.0×10^08
1.0×10^07
KLH
R22
*
CD5dull B220+ Leukemia %
100
80
60
40
20
0
KLH
R22
*

FIG. 34



KLH-1
KLH-2
KLH-3
KLH-4
R22-1
R22-2
R22-3
R22-4
FL2-H: B220 PE
FL4-H: ROR1 A647

FIG. 35



Down-modulation of ROR1 in WT B6 Mice
Immunized with R22
KLH
R22-KLH
% Max
FL4-H 4A5 A647A
MFI
KLH
R22-KLH
*

FIG. 36



A
KLH-1
KLH-2
KLH-3
KLH-4
R22-1
R22-2
R22-3
R22-4
FL2-H: CD8 PE
FL1-H: CD3 FITC
B
CD8+ in vivo p=0.0004
CD8+ lymphocyte %
15
10
5
0
KLH
R22

FIG. 37

Group	Mouse	Number	Immunization	Injection	Amount
1	ROR1-Tg	N=5	(-)	(-)	(-)
2	ROR1-Tg	N=5	KLH	s.c	100 μg/mouse
3	ROR1-Tg	N=5	R22-KLH	s.c	100 μg/mouse




FIG. 38



KLH-1
KLH-2
KLH-3
KLH-4
KLH-5
R22-1
R22-2
R22-3
R22-4
R22-5
FL3-H: CD5 PerCP
FL4-H: ROR1 A647

FIG. 39



Inhibition of Engraftment of ROR1+ Leukemia by R22 Vaccination in ROR1-Tg mice
Total Leukemia
% of Leukemia in Lymphocytes
CD5dull B220+ Leukemia (Total Cells/Spleen)
CD5dull B220+ Leukemia %
6x10^7
4x10^7
2x10^7
0
40
30
20
10
0
*
*
KLH
R22-KLH
KLH
R22-KLH

FIG. 40



Down-modulation of ROR1 in ROR1-Tg Mice
Immunized with R22
KLH
R22-KLH
% Max
FL4-H 4A5 A647A
MFI
KLH
R22-KLH
*

FIG. 41



KLH-1
KLH-2
KLH-3
KLH-4
R22-1
R22-2
R22-3
R22-4
FL2-H: B220 PE
FL1-H: CD3 FITC
T lymphocytes %
40
30
20
10
0
KLH
R22KLH
*

FIG. 42



A
KLH-1
KLH-2
KLH-3
KLH-4
R22-1
R22-2
R22-3
R22-4
FL3-H: CD4 PerCP
FL1-H: CD3 FITC
B
CD4+ Lymphocytes %
20
16
12
8
4
0
*
KLH
R22-KLH

FIG. 43



A
KLH-1
KLH-2
KLH-3
KLH-4
R22-1
R22-2
R22-3
R22-4
FL2-H: CD8 PE
FL1-H: CD3 FITC
B
CD8+ Lymphocytes %
KLH
R22-KLH
*

FIG. 44



A
Lung relapse by ROR1 status
% w/o Lung Relapse
100
80
60
40
p=0.002
ROR1L 0-33rd
ROR1M 34-67th
ROR1H 68-100th
Relapse status
n Yes No
ROR1L 194 25 169
ROR1M 194 23 172
ROR1H 194 39 155
p=0.03
0 20 40 60 80 100 120 140 160 180 200
Metastasis-free survival (months)
B
Bone relapse by ROR1 status
% w/o Bone Relapse
100
80
60
40
p=0.004
ROR1L 0-33rd
ROR1M 34-67th
ROR1H 68-100th
Relapse status
n Yes No
ROR1L 169 42 127
ROR1M 175 51 124
ROR1H 180 63 117
p=0.04
0 20 40 60 80 100 120 140 160 180 200
Metastasis-free survival (months)
C
Brain relapse by ROR1 status
% w/o Brain Relapse
100
80
60
40
p=0.04
ROR1L 0-33rd
ROR1M 34-67th
ROR1H 68-100th
Relapse status
n Yes No
ROR1L 169 7 162
ROR1M 183 9 174
ROR1H 172 14 158
p=0.24
0 20 40 60 80 100 120 140 160 180 200
Metastasis-free survival (months)

FIG. 45



A
p<0.0001
p<0.01
p<0.01
Normalized Expression Units
ER-/lo
ER+
PR-/lo
PR+
HER2-/lo
HER2+
B
Overall relapse by ER Status
ER-/lo
ER+
p=0.13
% w/o Relapse
Metastasis-free survival (months)
C
Overall relapse by ER and ROR1 Status
ER-/lo/ROR1 Low
ER-/lo/ROR1 Hi
ER+/ROR1 Low
ER+/ROR1 Hi
p<0.0001
% w/o Relapse
Metastasis-free survival (months)
D
Overall relapse by PR Status
PR-/lo
PR+
p=0.0007
% w/o Relapse
Metastasis-free survival (months)
E
Overall relapse by PR and ROR1Status
PR-/lo/ROR1 Low
PR-/lo/ROR1 Hi
PR+/ROR1 Low
PR+/ROR1 Hi
p<0.0001
% w/o Relapse
Metastasis-free survival (months)
F
Overall relapse by HER2 Status
HER2-/lo
HER2+
p=0.16
% w/o Relapse
Metastasis-free survival (months)
G
Overall relapse by Her2 and ROR1Status
HER2-/lo/ROR1 Low
HER2-/lo/ROR1 Hi
HER2+/ROR1 Low
HER2+/ROR1 Hi
p<0.0001
% w/o Relapse
Metastasis-free survival (months)

FIG. 46



A
MDA-MB-231
Parental
CTRL-shRNA1
CTRL-shRNA2
ROR1-shRNA1
ROR1-shRNA2
ROR1
β-actin
B
Relative mRNA level
CTRL-shRNA
ROR1-shRNA
2.0
1.5
1.0
0.5
0.0
*
**
VIM
KRT19

FIG. 47



A
CXCR4
Relative CXCR4 mRNA Level
1.5
1.0
0.5
0.0
**
CTRL-shRNA2
ROR1-shRNA2
B
ROR1-shRNA2
CTRL-shRNA2
Relative Cell Number
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
Fluorescence Intensity (CXCR4)
C
Migration to CXCL12
Relative Migration (%)
100
80
60
40
20
0
**
CTRL-shRNA2
ROR1-shRNA2

FIG. 48



A
MDA-MB-231
CTRL siRNA
ROR1 siRNA
mRNA Fold Changes
ROR1
SNAI1
SNAI2
ZEB1
ROR1
KRT19
CDH1
TJP1
VIM
CDH2
8h after Transfection
24h after Transfection
B
HS-578T
CTRL siRNA
ROR1 siRNA
mRNA Fold Changes
ROR1
SNAI1
SNAI2
ZEB1
ROR1
KRT19
CDH1
TJP1
VIM
CDH2
8h after Transfection
24h after Transfection
C
BT549
CTRL siRNA
ROR1 siRNA
mRNA Fold Changes
ROR1
SNAI1
SNAI2
ZEB1
ROR1
KRT19
CDH1
TJP1
VIM
CDH2
8h after Transfection
24h after Transfection

FIG. 49



A
Orthotopic Xenograft
MDA-MB-231 s.c. proliferation (1x 10⁶)
MDA-MB-231 s.c. proliferation (5x10⁵)
MDA-MB-231 s.c. proliferation (2.5x10⁵)
Normalized Photon Flux
Day
CTRL-shRNA n=13
ROR1-shRNA n=14
CTRL-shRNA n=4
ROR1-shRNA n=4
CTRL-shRNA n=8
ROR1-shRNA n=8
Experimental Metastasis
MDA-MB-231 i.v. metastasis (1x10⁶)
MDA-MB-231 i.v. metastasis (5x10⁵)
MDA-MB-231 i.v. metastasis (2.5x10⁵)
Low Image Photons / sec
CTRL-shRNA n=5
ROR1-shRNA n=5
CTRL-shRNA n=5
ROR1-shRNA n=7
CTRL-shRNA n=8
ROR1-shRNA n=8
B
Lung Metastasis On Day 21
Lung Weight Index (g/Kg)
p<0.0001
p=0.034
p<0.0001
p=0.0007
1E6
1E6
5E5
5E5
2.5E5
2.5E5
Normal
CTRL-shRNA
ROR1-shRNA
C
1x10⁶
5x10⁵
2.5x10⁵
CTRL-shRNA (10X)
ROR1-shRNA (10X)

FIG. 50



A
Ki67
Tunnel
CK-19
Vimentin
CTRL-shRNA X 40
RCR1-shRNA X 40
B
p-AKT
p-CREB
CTRL-shRNA X40
RCR1-shRNA x40
CTRL-shRNA X40
RCR1-shRNA x40

FIG. 51




FIG. 52




FIG. 53